Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 2

Montelukast in the management of allergic rhinitis

Authors Jaime A Lagos, Gailen D Marshall

Published 15 May 2007 Volume 2007:3(2) Pages 327—332

Jaime A Lagos, Gailen D Marshall

Division of Clinical Immunology and Allergy, University of Mississippi Medical Center, Jackson, MS, USA

Abstract: Allergic rhinitis is the most common atopic disorder seen in the outpatient clinic setting diagnosed by history, physical exam and objective testing. According to the Allergic Rhinitis and its Impact on Asthma (ARIA) document, it is classified by chronicity (intermittent or persistent), and severity which is based on symptoms and quality of life (mild, or moderate/severe). It has enormous socioeconomic costs and significant reduction in quality of life. Allergen avoidance should be implemented, particularly in children, to reduce level of exposure; unfortunately efforts are often inadequate. Montelukast, a novel medication, is an antagonist to the leukotriene receptor. It is nonsedating, dosed once daily, and has a safety profile similar in adults and children with approval down to 6 months of age. A review of the literature undoubtedly establishes montelukast as a viable alternative for the treatment of seasonal allergic rhinitis. Its benefits are equivalent to antihistamines, when used as monotherapy, but less than intranasal corticosteroids. The addition of an antihistamine to montelukast does appear to have added benefits and at times is reported to be equivalent to intranasal corticosteroids.

Keywords: allergic rhinitis, montelukast, management, drug therapy

Download Article [PDF] 

Readers of this article also read:

Insulin resistance and inflammation markers in myocardial infarction

Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Shurygina E, Barbarash O

Journal of Inflammation Research 2013, 6:83-90

Published Date: 17 June 2013

Dynamic contour tonometry in asymmetric glaucoma patients

Suzuki Jr ER, Suzuki CLB, Carlier D, Penha D, Parchen MAR, Batista WD, Agostini Netto J

Clinical Ophthalmology 2012, 6:555-559

Published Date: 11 April 2012

Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer

Thérèse H Franco, Ahmed Khan, Vishal Joshi, Beje Thomas

Therapeutics and Clinical Risk Management 2008, 4:1367-1370

Published Date: 5 December 2008

Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective

Fabio Ferrarese, Gioia Becchimanzi, Massimo Bernardo, Maria Anna Conte, Angela Gioia, et al

Therapeutics and Clinical Risk Management 2008, 4:665-671

Published Date: 8 August 2008

Atripla™ – HIV therapy in one pill

Boris Julg, Johannes R Bogner

Therapeutics and Clinical Risk Management 2008, 4:573-577

Published Date: 6 June 2008

Concurrent Chagas’ disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug

Alberto E Paniz-Mondolfi, Alexandra M Pérez-Álvarez, Oscar Reyes-Jaimes, Gustavo Socorro, Olga Zerpa, et al

Therapeutics and Clinical Risk Management 2008, 4:659-663

Published Date: 6 June 2008

Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder

Renzo Colombo, Richard Naspro, Piera Bellinzoni, Fabio Fabbri, Giorgio Guazzoni, et al

Therapeutics and Clinical Risk Management 2007, 3:1003-1007

Published Date: 15 January 2008

Infliximab in the treatment of Crohn’s disease

Gilberto Poggioli, Silvio Laureti, Massimo Campieri, Filippo Pierangeli, Paolo Gionchetti, et al

Therapeutics and Clinical Risk Management 2007, 3:301-308

Published Date: 15 May 2007

Cost-benefit analysis of influenza vaccination in a public healthcare unit

Giorgio L Colombo, Antonio Ferro, Marta Vinci, Maria Zordan, Giulio Serra

Therapeutics and Clinical Risk Management 2006, 2:219-226

Published Date: 15 June 2006